What question did this study set out to answer?

To characterize the spectrum of intermediate epithelial-mesenchymal transition states in ovarian cancer and evaluate therapeutic strategies to reverse aggressive intermediate phenotypes.

November 7, 2013Cell Death and DiseaseOpen Access

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

View Full Paper

Ask AI

Bookmark

Authors

RHRuby Yun‐Ju HuangNational Taiwan University MWM. K. WongKK Women's and Children's Hospital TTTuan Zea TanNational University of Singapore

Discussion

Member takes

Implication

Preclinical investigation demonstrates that saracatinib restores E-cadherin and blocks spheroid formation in intermediate mesenchymal ovarian cancer cells, highlighting a targeted EMT reversal...

Key Points

To characterize the spectrum of intermediate epithelial-mesenchymal transition states in ovarian cancer and evaluate therapeutic strategies to reverse aggressive intermediate phenotypes.
Phenotypically characterized the EMT spectrum across 43 ovarian cancer cell lines, classifying them into Epithelial, Intermediate E, Intermediate M, and Mesenchymal subgroups.
Assessed anoikis resistance and spheroidogenesis in Intermediate M cells and evaluated the effect of the Src-kinase inhibitor saracatinib (AZD0530) in vitro and in vivo.
Applied a 33-gene EMT signature to an ovarian cancer patient cohort to assess correlation with progression-free survival.
Intermediate M cells exhibited high N-cadherin and ZEB1 with low E-cadherin and ERBB3/HER3, showing increased anoikis resistance and spheroidogenesis.
Saracatinib restored E-cadherin expression in Intermediate M cells in vitro and in vivo while abrogating spheroidogenesis.
The 33-gene EMT signature sub-classified ovarian cancer cohorts into four EMT states that correlated with progression-free survival.

Cite This Study

Huang et al. (2013) studied this question.

synapsesocial.com/papers/6a89a08d439f8b7e014330b2 https://doi.org/10.1038/cddis.2013.442

View Full Paper

Ask AI

Bookmark

Implication

Preclinical investigation demonstrates that saracatinib restores E-cadherin and blocks spheroid formation in intermediate mesenchymal ovarian cancer cells, highlighting a targeted EMT reversal...

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

Discussion

Member takes

Implication

Key Points

Cite This Study

An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider